As announced in July, the European Medicines Agency approved Omeros' Pediatric Investigation Plan to study the use of OMS302 in pediatric patients, which is expected to lead to additional marketing exclusivity in Europe. Omeros has OMS302 marketing applications under review in the U.S. and Europe with anticipated market launch in 2014. Results of the pediatric studies are expected to be available during the post marketing period.
Recent OMER News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:08:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:06:56 PM
- Omeros Corporation Reports Second Quarter 2024 Financial Results • Business Wire • 08/07/2024 08:02:00 PM
- Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 • Business Wire • 08/05/2024 08:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:48:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:13:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:12:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:10:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:08:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:07:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:05:53 PM
- Omeros Announces Webcast Details for Annual Meeting of Shareholders • Business Wire • 06/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 01:00:24 PM
- Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 • Business Wire • 06/03/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:09:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:07:40 PM
- Omeros Corporation Reports First Quarter 2024 Financial Results • Business Wire • 05/15/2024 08:02:00 PM
- Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 • Business Wire • 05/10/2024 12:50:00 PM
- Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress • Business Wire • 05/09/2024 12:50:00 PM
- Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results • Business Wire • 04/01/2024 08:02:00 PM
- Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 • Business Wire • 03/27/2024 12:30:00 PM
- Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy • Business Wire • 02/20/2024 02:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:05:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:00:23 PM
- Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust • Business Wire • 02/01/2024 02:11:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM